During Digestive Disease Week 2019, held May 18-21 in San Diego, California, researchers presented the 1-year results of a phase 1 trial of subcutaneous CT-P13 versus the intravenous formulation of the biosimilar in patients with Crohn disease (CD).
Celltrion’s proposed subcutaneous formulation of its infliximab biosimilar, CT-P13 (Remsima, Inflectra) is currently under European Medicines Agency evaluation, and the proposed formulation of the drug will also be studied in the United States in a phase 3 program in patients with inflammatory bowel disease.
During Digestive Disease Week 2019, held May 18-21 in San Diego, California, researchers presented the 1-year results of a phase 1 trial of subcutaneous CT-P13 versus the intravenous formulation of the biosimilar in patients with Crohn disease (CD).1
Patients (n = 44) who had moderate to severe CD—defined as a Crohn Disease Activity Index score of 220 to 450—were given IV CT-P13 at 5 mg/kg at weeks 0 and 2, then randomized into 4 cohorts of 11 patients each.
One cohort continued to receive the IV biosimilar every 8 weeks, while the second, third, and fourth cohorts each received the subcutaneous biosimilar at doses of 120 mg, 180 mg, and 240 mg, respectively, every 2 weeks up to week 54.
At week 30, overall clinical response rates among cohorts were similar. Clinical remission was numerically higher in the subcutaneous therapy cohorts at week 54 (8 patients, 7 patients, and 4 patients in the respective subcutaneous groups versus 4 patients in the IV group).
The mean predose serum concentration of infliximab before the next dose was higher in the subcutaneous cohorts throughout the study versus the IV group. Ctrough levels increased as the subcutaneous dose increased, and were substantially higher than the target therapeutic concentration.
The safety profiles of the IV and subcutaneous formulations were comparable, and 11.4% of patients had injection-site reactions, all in the subcutaneous administration group.
The authors concluded that the novel formulation of the biosimilar infliximab had similar efficacy and safety to the IV formulation at 1 year, and that this formulation could expand treatment options for patients with CD by providing high consistency in drug exposure during maintenance therapy.
In addition to making an appealing choice for patients who are satisfied with treatment with intravenous infliximab but who prefer or need a subcutaneous route of administration, the new formulation of CT-P13, said Celltrion in a recent statement, could compete with brand-name adalimumab (Humira), another subcutaneously administered anti—tumor necrosis factor therapy.
Reference
1. Byong DY, Byung IJ, Borzan V, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase 1 open-label randomized controlled trial in patients with active Crohn’s disease. Presented at: Digestive Disease Week 2019, San Diego, California, May 18-21, 2019. Abstract Tu1715.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.